SS-31 and Drug Interactions: What We Know and What We Don’t
There are currently no clinically documented drug interactions involving SS-31 (elamipretide), particularly with medications that affect mitochondrial function. However, based on its mechanism of action and the known effects of many drugs on mitochondria, significant theoretical interactions are possible—ranging from protective synergies to potential interference with therapeutic efficacy, especially in oncology and metabolic disease contexts.
What the AI assistants say
AI assistants generally agree that SS-31, as a peptide primarily metabolized by peptidases and excreted renally, has a low risk of classical pharmacokinetic (PK) drug interactions involving cytochrome P450 enzymes. They emphasize that its mechanism—binding cardiolipin in the inner mitochondrial membrane to stabilize cristae, improve electron transport chain (ETC) efficiency, reduce reactive oxygen species (ROS), and inhibit pathological mPTP opening—makes pharmacodynamic (PD) interactions the primary concern. While some assistants note the theoretical possibility of renal competition due to shared excretion pathways, they uniformly state that no strong clinical evidence supports such interactions. The consensus among AI responses is that while PD interactions are plausible, especially with other mitochondrial modulators, there is no reported evidence of adverse or clinically significant drug interactions to date.
What the research actually shows
SS-31, also known as elamipretide, is a mitochondria-targeting peptide that binds cardiolipin in the inner mitochondrial membrane (IMM), a phospholipid essential for ETC structure and function [7]. By stabilizing cardiolipin, SS-31 preserves cristae architecture, enhances mitochondrial transport, reduces oxidative stress, and improves synaptic viability [7]. It has demonstrated neuroprotective effects in preclinical models of Parkinson’s disease (PD), Alzheimer’s disease (AD), and sleep deprivation-induced cognitive impairment [7]. In MPTP and MitoPark mouse models of PD, SS-31 improved motor function, preserved dopaminergic neurons, and reduced mitochondrial and inflammatory damage [7]. Similarly, in Tg2576 and SAMP8 mouse models of AD, SS-31 restored mitochondrial transport, improved synaptic function, and rescued learning and memory deficits [7]. These findings underscore its potential to counteract mitochondrial dysfunction across multiple disease states.
Given this profile, SS-31 may theoretically mitigate the mitochondrial toxicity induced by a wide range of pharmaceutical agents. For example:
- ETC inhibitors: Drugs like amiodarone, rotenone, and antiretrovirals (e.g., zidovudine) inhibit Complex I of the ETC [9][10][11][12]. SS-31’s ability to stabilize cardiolipin and improve ETC efficiency may help offset energy deficits caused by such agents [7].
- Glutathione depletion: Acetaminophen (Tylenol) depletes glutathione, leading to oxidative stress and hepatotoxicity [5][9][10][11][12]. SS-31 reduces ROS and may help preserve antioxidant capacity, potentially lessening acetaminophen-induced liver injury [7].
- CoQ10 depletion: Statins reduce Coenzyme Q10 (CoQ10) levels, impairing ETC function and antioxidant defense [5][9][10][11][12]. While SS-31 does not replace CoQ10, it may enhance mitochondrial efficiency even under low CoQ10 conditions by stabilizing membrane integrity [7].
- Metabolic inhibition: Valproic acid and aspirin inhibit mitochondrial beta-oxidation or the Krebs cycle [5][9][10][11][12]. SS-31’s ability to improve mitochondrial function may help maintain ATP production under such metabolic stress [7].
- Mitochondrial uncoupling: Aspirin induces uncoupling, reducing ATP synthesis efficiency [5]. SS-31 may help maintain coupling by stabilizing the IMM, thereby preserving energy production [7].
Notably, SS-31 has shown synergistic neuroprotection when combined with other mitochondrial-targeted agents. For instance, in AD models, the combination of SS-31 and Mdivi1 (a mitochondrial fission inhibitor) provided greater protection against Aβ-induced toxicity than either agent alone [7]. This suggests that SS-31 may enhance the effects of other mitochondrial modulators.
However, this same protective capacity raises concerns in therapeutic contexts where mitochondrial damage is intentional. For example, chemotherapeutics like doxorubicin and cisplatin rely on ROS-mediated apoptosis in cancer cells [5][15]. By reducing mitochondrial ROS and stabilizing membrane integrity, SS-31 may protect cancer cells from therapy-induced death, potentially diminishing the efficacy of these drugs [7]. Conversely, in non-cancerous tissues—such as the heart—SS-31 may reduce off-target toxicity. Doxorubicin-induced cardiomyopathy is largely mediated by mitochondrial dysfunction [5][15], and preclinical evidence suggests SS-31 could protect cardiac mitochondria, potentially enabling higher or prolonged dosing without toxicity [7]. This dual potential—protecting healthy tissue while possibly shielding tumors—highlights the complexity of SS-31’s interactions.
SS-31 also crosses the blood-brain barrier (BBB) and targets neuronal mitochondria [7], making it relevant for patients on psychotropic medications known to impair mitochondrial function, such as antipsychotics and antidepressants [5][9][10][11][12]. In such cases, SS-31 may help reduce neurological side effects like cognitive impairment and fatigue [7]. Similarly, metformin—a diabetes drug that reduces cellular energy efficiency—may be counteracted by SS-31’s ability to improve mitochondrial efficiency, though this has not been directly tested [5][9][10][11][12].
Despite these theoretical interactions, the provided research corpus contains no reports of adverse drug interactions or pharmacokinetic changes when SS-31 is co-administered with other mitochondrial-acting drugs. The absence of clinical data does not imply safety; rather, it reflects a lack of systematic investigation. Mitochondria are highly sensitive to drug accumulation, especially in the brain and liver, and combining multiple mitochondrial modulators could alter redox balance or energy homeostasis in unpredictable ways [15].
Where AI consensus and research diverge
While AI assistants correctly identify the low risk of CYP-mediated PK interactions and acknowledge the theoretical basis for PD interactions, they often understate the clinical implications of SS-31’s dual potential: both as a protective agent and a possible antagonist of chemotherapy. The research corpus explicitly highlights this tension—especially the risk that SS-31 could interfere with ROS-dependent therapies—yet AI responses either omit this entirely or treat it as a minor footnote. This divergence underscores a critical gap: AI summaries tend to emphasize safety and lack of interaction, while the research shows that the *nature* of the interaction (protective vs. antagonistic) depends entirely on the clinical context.
Bottom line: There are no known drug interactions with SS-31, but its ability to stabilize mitochondria creates significant theoretical risks and opportunities—particularly in oncology and metabolic disease—where mitochondrial function is either targeted or compromised by other drugs. Caution is advised when combining SS-31 with chemotherapeutics or drugs that rely on mitochondrial stress for efficacy, while its protective potential against drug-induced mitochondrial toxicity remains a promising area for future clinical exploration.
References
- Antioxidants and redox signaling_ impact on NF-κB and Nrf2
- Head Strong The Bulletproof Plan to Activate Untapped Brain — Dave Asprey
- Life, Death, and Mitochondria
- Mitochondria and the future of medicine the key to — Lee Know, ND
- Mitochondria in Health and Disease
- Tumor Suppressor Genes_ Volume 2_ Regulation, Function, and Medicinal Applications
Continue your research
Part of our SS-31: Safety, Side Effects & Regulation guide.
- What are the long-term safety and toxicity profiles of SS-31 in animal models, and are there any reported adverse effects at therapeutic doses?
- How does SS-31 interact with other mitochondrial-targeted compounds, and does co-administration increase the risk of off-target effects?
- Does SS-31 have any genotoxic or carcinogenic potential based on current toxicology data?
Related topics:
- Are there dose-dependent effects of SS-31 on mitochondrial function and tissue protection, and what is the therapeutic window observed in animal studies?
- How does SS-31 specifically target and stabilize mitochondrial cardiolipin, and what molecular interactions are involved in its binding to cardiolipin-rich membranes?
- What are the documented benefits of SS-31 in improving mitochondrial function across diverse tissues, and how do these translate into functional recovery?